CTIS2023-505781-28-00进行中（未招募）1 期
FILOWM4-WaZaBi
French Innovative Leukemia Organization0 个研究点目标入组 102 人开始时间: 2024年3月14日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 102
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
招募中
1 期
A study in healthy subjects investigating the safety, tolerability and concentrations of FE 999301 after single and multiple dosesInflammatory Gastrointestinal DiseaseMedDRA version: 20.0Level: HLGTClassification code: 10017969Term: Gastrointestinal inflammatory conditions Class: 10017947CTIS2023-507882-24-00Ferring Pharmaceuticals A/S48
招募中
1 期
Single-dose Study of BMS-986326 at Two Dose Levels in Participants with Atopic DermatitisAtopic DermatitisCTIS2022-502997-18-00Bristol-Myers Squibb Services Unlimited Company64
进行中（未招募）
1 期
A phase 1/phase 2 study to investigate safety, tolerability and efficacy with TG01/QS-21 vaccine administration in patients with confirmed KRAS or NRAS codon 12/13 mutation and high-risk smoldering multiple myeloma or multiple myeloma and evidence of measurable disease = 1 line of treatment.multiple myelomaCTIS2022-502275-39-00Oslo University Hospital Hf20
进行中（未招募）
1 期
An open label, balanced, randomized, two-treatment, two-period, two-sequence, single dose crossover bioequivalence study comparing Lamotrigine Dispersible Tablets BP 100 mg, manufactured by Sun Pharmaceutical Industries Limited, India with Lamictal (Lamotrigine) Dispersible Tablets 100 mg, Manufactured by: Delpharm Poznaÿ – Poland & Registered and Imported by: GlaxoSmithKline Brasil Ltda, in healthy adult, human subjects under fasting condition.CTIS2024-513106-62-00Sun Pharmaceutical Industries Limited30
进行中（未招募）
1 期
A Multi-arm Phase 1b Study of Talquetamab With Other Anticancer Therapies in Participants with Multiple Myelomamultiple myelomaCTIS2023-503620-60-00Janssen - Cilag International182